| scholarly article | Q13442814 |
| P50 | author | Paul Gregorevic | Q72997203 |
| P2093 | author name string | Jeffrey S Chamberlain | |
| James M Allen | |||
| Simone Abmayr | |||
| P2860 | cites work | Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. | Q52547348 |
| Transcription initiation in the two leader exons of the rat IGF-I gene occurs from disperse versus localized sites | Q70146015 | ||
| Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury | Q77974446 | ||
| Loss of myostatin attenuates severity of muscular dystrophy in mdx mice | Q78560906 | ||
| Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function | Q24642759 | ||
| Interactions between beta 2-syntrophin and a family of microtubule-associated serine/threonine kinases | Q28139505 | ||
| Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy | Q29619282 | ||
| Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals | Q30050310 | ||
| Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle | Q31929653 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. | Q34190967 | ||
| Insulin-like growth factor-I in muscle metabolism and myotherapies. | Q34329895 | ||
| Systemic delivery of genes to striated muscles using adeno-associated viral vectors. | Q34347199 | ||
| Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model | Q35573761 | ||
| Two insulin-like growth factor I messenger RNAs are expressed in human liver | Q35583911 | ||
| Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. | Q36017254 | ||
| Forced expression of dystrophin deletion constructs reveals structure-function correlations. | Q36237129 | ||
| Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain | Q36293809 | ||
| Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice | Q36324105 | ||
| Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. | Q36968852 | ||
| Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy | Q37574344 | ||
| Regeneration of single skeletal muscle fibers in vitro | Q39945884 | ||
| Sequences of liver cDNAs encoding two different mouse insulin-like growth factor I precursors | Q40419087 | ||
| The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors | Q40559475 | ||
| Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. | Q40767544 | ||
| Dystrophin expression in muscle following gene transfer with a fully deleted ("gutted") adenovirus is markedly improved by trans-acting adenoviral gene products. | Q40780142 | ||
| Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors | Q41169594 | ||
| Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene | Q44020748 | ||
| Functional improvement of dystrophic muscle by myostatin blockade. | Q44234792 | ||
| IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. | Q44853225 | ||
| Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. | Q45023070 | ||
| AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype | Q45127732 | ||
| Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. | Q45571369 | ||
| Development of multiple cloning site cis-vectors for recombinant adeno-associated virus production | Q45730844 | ||
| Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice | Q45731049 | ||
| Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice | Q45733070 | ||
| Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector | Q45855552 | ||
| Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy | Q45883916 | ||
| Balancing muscle hypertrophy and atrophy | Q47413278 | ||
| Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. | Q50487651 | ||
| Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. | Q50518352 | ||
| Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. | Q52200362 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 441-450 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery | |
| P478 | volume | 12 |
| Q36968836 | C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice |
| Q37624403 | Cell therapy strategies and improvements for muscular dystrophy. |
| Q33931629 | Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice |
| Q52564618 | Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy. |
| Q42437569 | Construction and analysis of compact muscle-specific promoters for AAV vectors |
| Q37693022 | Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF-1 |
| Q39998139 | Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES. |
| Q24598350 | Follistatin gene delivery enhances muscle growth and strength in nonhuman primates |
| Q92022211 | Functional muscle hypertrophy by increased insulin-like growth factor 1 does not require dysferlin |
| Q33831193 | Gene and cell-mediated therapies for muscular dystrophy. |
| Q34576814 | Gene therapy progress and prospects: Duchenne muscular dystrophy |
| Q36345325 | Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. |
| Q37280594 | Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease |
| Q26866358 | Internal ribosome entry site-based vectors for combined gene therapy |
| Q43268180 | Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins |
| Q33304058 | Long term expression of bicistronic vector driven by the FGF-1 IRES in mouse muscle |
| Q36670010 | Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors |
| Q92464608 | Micro-dystrophin Gene Therapy Partially Enhances Exercise Capacity in Older Adult mdx Mice |
| Q37494390 | Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model |
| Q35569587 | MicroRNAs modulated by local mIGF-1 expression in mdx dystrophic mice |
| Q37643467 | Molecular cardiology in translation: gene, cell and chemical-based experimental therapeutics for the failing heart. |
| Q37257159 | Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice |
| Q26824503 | Pharmacology of manipulating lean body mass |
| Q34575694 | Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting |
| Q33690975 | Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy |
| Q37087939 | Progress and prospects: gene therapy for performance and appearance enhancement |
| Q38264369 | Prospect for pharmacological therapies to treat skeletal muscle dysfunction |
| Q92489474 | Recent advances in Duchenne muscular dystrophy |
| Q30557792 | Reduced IGF signaling prevents muscle cell death in a Caenorhabditis elegans model of muscular dystrophy |
| Q45861904 | Soluble TNF-α receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer |
| Q40966771 | Stem Cells and Tissue Niche: Two Faces of the Same Coin of Muscle Regeneration. |
| Q64897090 | The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. |
| Q37134005 | Toward exascale production of recombinant adeno-associated virus for gene transfer applications |
| Q36448393 | Treatment of human disease by adeno-associated viral gene transfer |
| Q35847178 | Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances |
Search more.